Literature DB >> 19490935

A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches.

Laurie Scott1, Chantra Eskes, Sebastian Hoffmann, Els Adriaens, Nathalie Alepée, Monica Bufo, Richard Clothier, Davide Facchini, Claudine Faller, Robert Guest, John Harbell, Thomas Hartung, Hennicke Kamp, Béatrice Le Varlet, Marisa Meloni, Pauline McNamee, Rosemarie Osborne, Wolfgang Pape, Uwe Pfannenbecker, Menk Prinsen, Christopher Seaman, Horst Spielmann, William Stokes, Kevin Trouba, Christine Van den Berghe, Freddy Van Goethem, Marco Vassallo, Pilar Vinardell, Valérie Zuang.   

Abstract

In spite of over 20 years of effort, no single in vitro assay has been developed and validated as a full regulatory replacement for the Draize Eye Irritation test. However, companies have been using in vitro methods to screen new formulations and in some cases as their primary assessment of eye irritation potential for many years. The present report shows the outcome of an Expert Meeting convened by the European Centre for the Validation of Alternative Methods in February 2005 to identify test strategies for eye irritation. In this workshop test developers/users were requested to nominate methods to be considered as a basis for the identification of such testing strategies. Assays were evaluated and categorized based on their proposed applicability domains (e.g., categories of irritation severity, modes of action, chemical class, physicochemical compatibility). The analyses were based on the data developed from current practice and published studies, the ability to predict depth of injury (within the applicable range of severity), modes of action that could be addressed and compatibility with different physiochemical forms. The difficulty in predicting the middle category of irritancy (e.g. R36, GHS Categories 2A and 2B) was recognized. The testing scheme proposes using a Bottom-Up (begin with using test methods that can accurately identify non-irritants) or Top-Down (begin with using test methods that can accurately identify severe irritants) progression of in vitro tests (based on expected irritancy). Irrespective of the starting point, the approach would identify non-irritants and severe irritants, leaving all others to the (mild/moderate) irritant GHS 2/R36 categories.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19490935     DOI: 10.1016/j.tiv.2009.05.019

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  20 in total

Review 1.  In vitro reconstructed 3D corneal tissue models for ocular toxicology and ophthalmic drug development.

Authors:  Yulia Kaluzhny; Mitchell Klausner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-02-05       Impact factor: 2.416

2.  Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.

Authors:  Susanne N Kolle; Robert Landsiedel
Journal:  Handb Exp Pharmacol       Date:  2021

3.  Polyaphron Formulations Stabilised with Different Water-Soluble Polymers for Ocular Drug Delivery.

Authors:  Roman V Moiseev; Fraser Steele; Vitaliy V Khutoryanskiy
Journal:  Pharmaceutics       Date:  2022-04-24       Impact factor: 6.525

4.  Integrated testing strategies for safety assessments.

Authors:  Thomas Hartung; Tom Luechtefeld; Alexandra Maertens; Andre Kleensang
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

Review 5.  Validating and troubleshooting ocular in vitro toxicology tests.

Authors:  Frank A Barile
Journal:  J Pharmacol Toxicol Methods       Date:  2010-01-22       Impact factor: 1.950

6.  Comparison of in vitro and in vivo phototoxicity tests with S-(-)-10,11-dihydroxyfarnesic acid methyl ester produced by Beauveria bassiana KACC46831.

Authors:  Min-A Kim; Hyeong-U Son; Cheol-Sik Yoon; Sung-Hee Nam; Young-Cheol Choi; Sang-Han Lee
Journal:  Biomed Rep       Date:  2014-06-20

7.  Validation of the OptiSafe™ eye irritation test.

Authors:  Neepa Choksi; Stewart Lebrun; Minh Nguyen; Amber Daniel; George DeGeorge; Jamin Willoughby; Adrienne Layton; Donnie Lowther; Jill Merrill; Joanna Matheson; João Barroso; Krystle Yozzo; Warren Casey; David Allen
Journal:  Cutan Ocul Toxicol       Date:  2020-07-16       Impact factor: 1.820

Review 8.  Role of In Vitro Models for Development of Ophthalmic Delivery Systems.

Authors:  Shallu Kutlehria; Mandip Singh Sachdeva
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2021       Impact factor: 4.889

9.  Comparison of the toxicity of aqueous and ethanol fractions of Angelica keiskei leaf using the eye irritancy test.

Authors:  Hyeong-U Son; Eun-Kyung Yoon; Yong-Soo Cha; Min-A Kim; Yong-Kyu Shin; Jong-Myung Kim; Yong-Hee Choi; Sang-Han Lee
Journal:  Exp Ther Med       Date:  2012-08-20       Impact factor: 2.447

Review 10.  The 3R principle: advancing clinical application of human pluripotent stem cells.

Authors:  Michael D O'Connor
Journal:  Stem Cell Res Ther       Date:  2013-03-08       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.